https://www.selleckchem.com/pr....oducts/gilteritinib-
osed at this tertiary referral center (2.3%). None of the NIFTP cohort experienced an adverse oncologic event, and there were no regional or distant metastases. Over 50% of patients with NIFTP received RAI. Thus, the NIFTP re-classification may substantially reduce the number of patients who require adjuvant therapies, such as completion surgery or RAI.Background and purpose The effects of direct oral anticoagulants in nonvalvular atrial fibrillation should be assessed in actual conditions of use. France has near-universal